Urogen Pharma Ltd (NASDAQ:URGN) CFO Peter P. Pfreundschuh Sells 1,416 Shares

Urogen Pharma Ltd (NASDAQ:URGN) CFO Peter P. Pfreundschuh sold 1,416 shares of Urogen Pharma stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $33.07, for a total transaction of $46,827.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

URGN traded down $0.42 on Thursday, reaching $32.13. 8,758 shares of the company traded hands, compared to its average volume of 175,984. The stock’s 50 day moving average price is $32.90 and its 200-day moving average price is $36.44. Urogen Pharma Ltd has a 52-week low of $30.48 and a 52-week high of $55.49. The company has a market cap of $449.49 million, a price-to-earnings ratio of -6.69 and a beta of 1.21.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Friday, August 9th. The company reported ($1.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.20) by $0.12. The company had revenue of $0.02 million for the quarter. On average, sell-side analysts anticipate that Urogen Pharma Ltd will post -4.95 earnings per share for the current year.

Several research firms have recently weighed in on URGN. JPMorgan Chase & Co. began coverage on shares of Urogen Pharma in a research report on Thursday, May 30th. They issued a “neutral” rating and a $41.00 target price on the stock. Zacks Investment Research downgraded shares of Urogen Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, July 30th. Cowen reaffirmed a “buy” rating on shares of Urogen Pharma in a research report on Monday, May 6th. Goldman Sachs Group started coverage on shares of Urogen Pharma in a research report on Wednesday, May 29th. They set a “neutral” rating and a $50.00 price objective on the stock. Finally, HC Wainwright set a $75.00 price objective on shares of Urogen Pharma and gave the company a “buy” rating in a research report on Tuesday, May 28th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $59.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of URGN. Public Employees Retirement Association of Colorado acquired a new stake in Urogen Pharma in the first quarter valued at approximately $41,000. Bank of Montreal Can acquired a new stake in Urogen Pharma in the second quarter valued at approximately $56,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Urogen Pharma by 112.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,421 shares of the company’s stock valued at $89,000 after acquiring an additional 1,282 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Urogen Pharma by 50.0% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 3,000 shares of the company’s stock valued at $108,000 after acquiring an additional 1,000 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in Urogen Pharma in the second quarter valued at approximately $170,000.

About Urogen Pharma

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Read More: What is Cost of Goods Sold (COGS)?

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.